Accelerated Pharma (Accelerated Pharma) Price-to-Tangible-Book : (As of May. 17, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Price-to-Tangible-Book?

As of today (2024-05-17), Accelerated Pharma's share price is $0.00. Accelerated Pharma's Tangible Book per Share of Mar. 2017 for the quarter that ended in Mar. 2017 was $-1.02. Hence, Accelerated Pharma's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Accelerated Pharma's Price-to-Tangible-Book or its related term are showing as below:

ACCP's Price-to-Tangible-Book is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.36
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Accelerated Pharma's share price is $0.00. Accelerated Pharma's Book Value per Sharefor the quarter that ended in Mar. 2017 was $-1.02. Hence, Accelerated Pharma's P/B Ratio of today is .

Accelerated Pharma Price-to-Tangible-Book Historical Data

The historical data trend for Accelerated Pharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Price-to-Tangible-Book Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Price-to-Tangible-Book

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Price-to-Tangible-Book	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Accelerated Pharma's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Price-to-Tangible-Book falls into.

Accelerated Pharma Price-to-Tangible-Book Calculation

Accelerated Pharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2017 )
	=	0.00	/	-1.015
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Accelerated Pharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines